[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341756-105":59,"doc-detail-341756-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","usp36-promotes-tumorigenesis-and-tamoxifen-resistance-in-breast-cancer-by-deubiquitinating-and-stabilizing-er","USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα","","Breast cancer therapy is limited by acquired tamoxifen resistance in about 30–40% of ER+ cases, where sustained estrogen receptor alpha (ERα) signaling and endocrine-resistant biology undermine selective estrogen receptor modulators. This study examines how post-translational regulation of ERα protein stability and transcriptomic output is controlled by the balance of E3 ubiquitin ligases and deubiquitinases, focusing on USP36. Using cell models, DUB siRNA screening, xenografts, and endocrine-resistant systems, the work identifies USP36 as a key driver of ERα-dependent progression and tamoxifen resistance, and shows that USP36 silencing suppresses tumorigenesis and restores drug sensitivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/usp36-promotes-tumorigenesis-and-tamoxifen-resistance-in-breast-cancer-by-deubiquitinating-and-stabilizing-er/341756/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/usp36-promotes-tumorigenesis-and-tamoxifen-resistance-in-breast-cancer-by-deubiquitinating-and-stabilizing-er/341756.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is tamoxifen resistance a major issue in ER+ breast cancer?","Question",{"text":112,"@type":113},"Approximately 30–40% of ER+ breast cancers recur after tamoxifen therapy. The document links resistance to alterations in endocrine signaling, particularly involving ERα regulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does USP36 play according to this study?",{"text":117,"@type":113},"USP36 is identified as a key deubiquitinase that promotes breast cancer progression through ERα signaling. The catalytically inactive mutant does not produce the same promoting effect.",{"name":119,"@type":110,"acceptedAnswer":120},"How does USP36 affect ERα stability and tamoxifen sensitivity?",{"text":121,"@type":113},"Silencing USP36 destabilizes the resistant ERα form (Y537S) and restores sensitivity to tamoxifen. Mechanistically, USP36 inhibits K48-linked polyubiquitination of ERα and enhances ERα transcriptome activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341756,1790146392,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Zhuang et al. J Exp Clin Cancer Res (2024) 43:249 [https://doi.org/10.1186/s13046-024-03160-2](https://doi.org/10.1186/s13046-024-03160-2)  \nJournal of Experimental & Clinical Cancer Research  \n RESEARCH Open Access  \nUSP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα  \nTing Zhuang1,2†, Shuqing Zhang1,2†, Dongyi Liu3,4†, Zhongbo Li1,2, Xin Li1,2, Jiaoyan Li1,2, Penghe Yang1,2, Chenmiao Zhang1,2, Jiayao Cui1,2, Mingxi Fu1,2, Fangyu Shen1,2, Lei Yuan5, Zhao Zhang6, Peng Su7*, Jian Zhu4,8* and Huijie Yang1,2*  \nAbstract  \nBackground Breast cancer is the most prevalent cancer in women globally. Over-activated estrogen receptor (ER)α signaling is considered the main factor in luminal breast cancers, which can be effectively managed with selective estrogen receptor modulators (SERMs) like tamoxifen. However, approximately 30–40% of ER + breast cancer cases are recurrent after tamoxifen therapy. This implies that the treatment of breast cancer is still hindered by resistance to tamoxifen. Recent studies have suggested that post-translational modifications of ERα play a significant role in endocrine resistance. The stability of both ERα protein and its transcriptome is regulated by a balance between E3 ubiquitin ligases and deubiquitinases. According to the current knowledge, approximately 100 deubiquitinases are encoded in the human genome, but it remains unclear which deubiquitinases play a critical role in estrogen signaling and endocrine resistance. Thus, decoding the key deubiquitinases that significantly impact estrogen signaling, including the control of ERα expression and stability, is critical for the improvement of breast cancer therapeutics.  \nMethods We used several ER positive breast cancer cell lines, DUB siRNA library screening, xenograft models, endocrine-resistant (ERα-Y537S) model and performed immunoblotting, real time PCR, RNA sequencing, immunofluorescence, and luciferase activity assay to investigate the function of USP36 in breast cancer progression and tamoxifen resistance.  \nResults In this study, we identify Ubiquitin-specific peptidase 36 (USP36) as a key deubiquitinase involved in ERα signaling and the advancement of breast cancer by deubiquitinases siRNA library screening. In vitro and in vivo studies showed that USP36, but not its catalytically inactive mutant (C131A), could promote breast cancer progression through ERα signaling. Conversely, silencing USP36 inhibited tumorigenesis. In models resistant to endocrine therapy,  \n†Ting Zhuang, Shuqing Zhang and Dongyi Liu contribute equally to the study.  \n*Correspondence:  \nPeng Su [supeng820125@163.com](supeng820125@163.com)[ ](supeng820125@163.com)Jian Zhu [jian.zhu@email.sdu.edu.cn](jian.zhu@email.sdu.edu.cn)[ ](jian.zhu@email.sdu.edu.cn)Huijie Yang [huijie.yang@xxmu.edu.cn](huijie.yang@xxmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://cre","cbCailavpqF6XMP4","https://ap.wps.com/l/cbCailavpqF6XMP4","pdf",5372913,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Background","[{\"question\":\"Why is tamoxifen resistance a major issue in ER+ breast cancer?\",\"answer\":\"Approximately 30–40% of ER+ breast cancers recur after tamoxifen therapy. The document links resistance to alterations in endocrine signaling, particularly involving ERα regulation.\"},{\"question\":\"What role does USP36 play according to this study?\",\"answer\":\"USP36 is identified as a key deubiquitinase that promotes breast cancer progression through ERα signaling. The catalytically inactive mutant does not produce the same promoting effect.\"},{\"question\":\"How does USP36 affect ERα stability and tamoxifen sensitivity?\",\"answer\":\"Silencing USP36 destabilizes the resistant ERα form (Y537S) and restores sensitivity to tamoxifen. Mechanistically, USP36 inhibits K48-linked polyubiquitination of ERα and enhances ERα transcriptome activity.\"}]","USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα | PDF",1790043578,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8620d63583dfe92b8291e85d91ce5c47.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a3b6ffe5725680363c8ffae96ad320a.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cb3b170687b19027e6322c43f06dc0f.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b33b7e3d1216e78a73e2b1007a753e33.webp",980,1301]